Treatment of severe genetic dyslipidemia: where are we going?

Ther Apher Dial. 2013 Apr;17(2):122-3. doi: 10.1111/1744-9987.12028.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Blood Component Removal / methods
  • Humans
  • Hyperlipoproteinemia Type II / genetics
  • Hyperlipoproteinemia Type II / physiopathology
  • Hyperlipoproteinemia Type II / therapy*
  • Hyperlipoproteinemias / genetics
  • Hyperlipoproteinemias / physiopathology
  • Hyperlipoproteinemias / therapy*
  • Lipoprotein(a) / blood
  • Severity of Illness Index

Substances

  • Lipoprotein(a)